Increased expression of tumor-associated antigens in pediatric and adult ependymomas: Implication for vaccine therapy

Journal of Neuro-Oncology

Volumn 111, Issue 2, 2013, Pages 103-111

  Yeung, Jacky T ^a   Hamilton, Ronald L ^a   Okada, Hideho ^a   Jakacki, Regina I ^b   Pollack, Ian F ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Ependymoma; EphA2; Interleukin 13 receptor alpha 2; Survivin; Tumor associated antigen; Wilms' Tumor 1

Indexed keywords

ANTIBODY; CELL PROTEIN; EPHRIN RECEPTOR A2; HLA ANTIGEN CLASS 1; INTERLEUKIN 13 RECEPTOR ALPHA2; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILMS TUMOR 1 PROTEIN; BIRC5 PROTEIN, HUMAN; CANCER VACCINE; IL13RA1 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 13 RECEPTOR ALPHA1; WT1 PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; MALE; MEDULLOBLASTOMA; PRESCHOOL CHILD; PROTEIN TARGETING; SCHOOL CHILD; AGE; BRAIN; BRAIN TUMOR; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BRAIN; BRAIN NEOPLASMS; CANCER VACCINES; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFANT; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; MALE; MIDDLE AGED; RECEPTOR, EPHA2; WT1 PROTEINS;

MLCS; MLOWN;

EID: 84879283790     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0998-x     Document Type: Article

References (40)

1. Hamilton RL, Pollack IF (1997) The molecular biology of ependymomas. Brain Pathol 7:807-822
2. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E (2005) Ependymal tumors in childhood. Pediatr Blood Cancer 45:298-303. doi: 10.1002/pbc.20212
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. doi: 10.1007/s00401-007- 0243-4
4. Poltinnikov IM, Merchant TE (2006) CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis. Pediatr Blood Cancer 47:169-173. doi: 10.1002/pbc.20587
5. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N (2005) Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 103:31-37. doi: 10.3171/jns.2005.103.1.0031
6. Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK (2009) Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 183:7428-7440. doi: 10.4049/jimmunol.0902811
7. Pollack I, Jakacki R, Butterfield L, Okada H (2012) Peptide vaccine therapy for childhood gliomas. J Neurosurg Pediatr A341 (abstract)
8. Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177-188
9. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J immunol 137:2299-2306
10. Bourne TD, Elias WJ, Lopes MB, Mandell JW (2010) WT1 is not a reliable marker to distinguish reactive from neoplastic astrocyte populations in the central nervous system. Brain Pathol 20:1090-1095. doi: 10.1111/j.1750-3639. 2010.00415.x
11. Dominique Charron (1996) 12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. Abstracts. Human immunology 47:1-184, Elsevier, New York
12. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V (2007) Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 67:5471-5478. doi: 10.1158/0008-5472.can-06-4735
13. Dodelet VC, Pasquale EB (2000) Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19:5614-5619. doi: 10.1038/sj.onc. 1203856
14. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H (2005) EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7:717-722
15. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88:245-250. doi: 10.1007/s11060-008-9566-9
16. Wykosky J, Gibo DM, Stanton C, Debinski W (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551. doi: 10.1158/1541-7786.mcr-05-0056
17. Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR (2008) Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol 88:65-76. doi: 10.1007/s11060-008-9534-4
18. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, Jiang X, Yu Y, Brosius A, Thomas M, Chin L, Brennan C, DePinho RA, Kohane I, Carroll RS, Black PM, Johnson MD (2006) A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66:10815-10823. doi: 10.1158/0008-5472.can-06-1408
19. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004) Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101:1036-1042. doi: 10.1002/cncr.20470
20. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H (2006) Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 66:5883-5891. doi: 10.1158/0008-5472.can-06-0363
21. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330-336. doi: 10.1200/jco.2010.30.7744
22. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10:1319-1328
23. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54. doi: 10.1038/nrc968
24. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA (2005) Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 124:543-549. doi: 10.1309/pp2g5gaafkv82dtg
25. Altura RA, Olshefski RS, Jiang Y, Boue DR (2003) Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer 89:1743-1749. doi: 10.1038/sj.bjc.6601334
26. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964-5968
27. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55:1294-1298. doi: 10.1007/s00262-005-0102-x
28. Alvarez-Buylla A, Garcia-Verdugo JM, Tramontin AD (2001) A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci 2:287-293. doi: 10.1038/35067582
29. Kaufman HL, Disis ML (2004) Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Investig 113:664-667. doi: 10.1172/jci21148
30. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804-814. doi: 10.1038/modpathol.3800588
31. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194-204
32. Scharnhorst V, van der Eb AJ, Jochemsen AG (2001) WT1 proteins: functions in growth and differentiation. Gene 273:141-161
33. Idowu MO, Rosenblum MK, Wei XJ, Edgar MA, Soslow RA (2008) Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct - a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. Am J Surg Pathol 32:710-718. doi: 10.1097/PAS.0b013e318159a2b4
34. Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, Capper D, Weller M, Meyermann R, Mittelbronn M (2009) Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol 35:69-81. doi: 10.1111/j.1365-2990.2008.00957.x
35. Hashiba T, Izumoto S, Kagawa N, Suzuki T, Hashimoto N, Maruno M, Yoshimine T (2007) Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med-Chir 47:165-170; discussion 170
36. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470-476. doi: 10.1002/(sici)1097-0215(19960516)66:4<470:aid-ijc10>3.0.co;2-c
37. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL, Tomai MA (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15:537-545
38. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C (2001) Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61:1095-1099
39. Yang I, Kremen TJ, Giovannone AJ, Paik E, Odesa SK, Prins RM, Liau LM (2004) Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100:310-319. doi: 10.3171/jns.2004.100.2.0310
40. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157-164